Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Trial · NCT03640481
Adverse events852
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 852
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Candida Infection | Infections and infestations | Adult Arm A: Belumosudil 200 mg QD | 5 | 77 | 7 |
| other | Candida Infection | Infections and infestations | Adult Arm B: Belumosudil 200 mg BID | 1 | 75 | 1 |
| other | Candida Infection | Infections and infestations | Adolescent Arm A: Belumosudil 200 mg QD | 0 | 2 | 0 |
| other | Candida Infection | Infections and infestations | Adolescent Arm B: Belumosudil 200 mg BID | 0 | 1 | 0 |
| other | Conjunctivitis | Infections and infestations | Adult Arm A: Belumosudil 200 mg QD | 6 | 77 | 7 |
| other | Conjunctivitis | Infections and infestations | Adult Arm B: Belumosudil 200 mg BID | 2 | 75 | 2 |
| other | Conjunctivitis | Infections and infestations | Adolescent Arm A: Belumosudil 200 mg QD | 0 | 2 | 0 |
| other | Conjunctivitis | Infections and infestations | Adolescent Arm B: Belumosudil 200 mg BID | 1 | 1 | 1 |
| other | Coronavirus Infection | Infections and infestations | Adult Arm A: Belumosudil 200 mg QD | 3 | 77 | 3 |
| other | Coronavirus Infection | Infections and infestations | Adult Arm B: Belumosudil 200 mg BID | 6 | 75 | 7 |
| other | Coronavirus Infection | Infections and infestations | Adolescent Arm A: Belumosudil 200 mg QD | 0 | 2 | 0 |
| other | Coronavirus Infection | Infections and infestations | Adolescent Arm B: Belumosudil 200 mg BID | 0 | 1 | 0 |
| other | Cytomegalovirus Infection Reactivation | Infections and infestations | Adult Arm A: Belumosudil 200 mg QD | 0 | 77 | 0 |
| other | Cytomegalovirus Infection Reactivation | Infections and infestations | Adult Arm B: Belumosudil 200 mg BID | 1 | 75 | 1 |
| other | Cytomegalovirus Infection Reactivation | Infections and infestations | Adolescent Arm A: Belumosudil 200 mg QD | 0 | 2 | 0 |
| other | Cytomegalovirus Infection Reactivation | Infections and infestations | Adolescent Arm B: Belumosudil 200 mg BID | 1 | 1 | 1 |
| other | Gastroenteritis | Infections and infestations | Adult Arm A: Belumosudil 200 mg QD | 4 | 77 | 4 |
| other | Gastroenteritis | Infections and infestations | Adult Arm B: Belumosudil 200 mg BID | 2 | 75 | 2 |
| other | Gastroenteritis | Infections and infestations | Adolescent Arm A: Belumosudil 200 mg QD | 0 | 2 | 0 |
| other | Gastroenteritis | Infections and infestations | Adolescent Arm B: Belumosudil 200 mg BID | 0 | 1 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03640481/events